Primary Care Clinics in Dayville, CT Accepting Medicare
4 Primary Care Clinics found. Showing 1 - 4
 Medical Center Of Northeast Connecticut Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 612 Hartford Pike, Dayville, CT 06241 Phone: 860-779-0284 Fax: 860-779-0386 |
Killingly Medical Center Llc Family Medicine Medicare: Medicare Enrolled Practice Location: 545 Hartford Pike, Dayville, CT 06241 Phone: 860-204-0883 |
Joseph Botta Md & Associates Llc Internal Medicine Medicare: Medicare Enrolled Practice Location: 150 Ware Rd, Dayville, CT 06241 Phone: 860-779-5093 Fax: 860-779-5095 |
Hope Medical Care Llc Clinic/Center - Primary Care Medicare: Medicare Enrolled Practice Location: 17 Ferland Dr, Dayville, CT 06241 Phone: 401-338-0673 |
News Archive
Pentagon plans 30-person team to tackle Ebola in U.S.
The defense department announced Sunday that it would create a team to assist U.S. doctors responding to new Ebola cases, while the government issued more stringent guidelines for protective garb for health care workers treating Ebola patients. In addition, The Wall Street Journal profiles a biologist who has been working since 1997 on an Ebola vaccine which has been proven to block the disease in monkeys.
High levels of education and income predict better cognitive skills for older Chinese people
According to a doctoral dissertation being examined at the University of Helsinki, Chinese people of a higher socioeconomic status are on average in better physical and cognitive condition at baseline. However, socioeconomic status does not protect people from age-related decreases in the ability to function.
FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence
The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).
Inotuzumab ozogamicin study reveals complete remission rates higher than standard therapy for ALL patients
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
› Verified 8 days ago